Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe Interaction

Drug interaction information between Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe.

Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe have a documented major interaction in FDA labeling.

FDA drug labeling documents a major-severity interaction between Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Glecaprevir/Pibrentasvir

NS3/4A/NS5A Inhibitor (HCV)

Drug B

Rosuvastatin/Ezetimibe

Statin / Cholesterol Absorption Inhibitor

How They Interact

These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.

FDA Label Information

Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.

Glecaprevir/Pibrentasvir Also Interacts With

View all Glecaprevir/Pibrentasvir interactions →

Frequently Asked Questions

What SPL severity band is on file for Glecaprevir/Pibrentasvir + Rosuvastatin/Ezetimibe?

Compiled FDA labeling labels this pair major. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Glecaprevir/Pibrentasvir has 38 labeled pairs on file vs Rosuvastatin/Ezetimibe's 12. In the major band specifically: Glecaprevir/Pibrentasvir has 3 (also Rifampin, Rosuvastatin); Rosuvastatin/Ezetimibe has 3 (also Sofosbuvir/Velpatasvir, Febuxostat).

What mechanism field is on file for Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe?

These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.

Glecaprevir/Pibrentasvir's labeled portfolio outnumbers Rosuvastatin/Ezetimibe

SPL source-record counts only. This page's band is major · classes on file: Glecaprevir/Pibrentasvir (NS3/4A/NS5A Inhibitor (HCV)); Rosuvastatin/Ezetimibe (Statin / Cholesterol Absorption Inhibitor).

Glecaprevir/Pibrentasvir

3 major · 9 moderate · 26 minor · 38 total

Rosuvastatin/Ezetimibe

3 major · 7 moderate · 2 minor · 12 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.